IBRX Reports $44.2M Net Product Revenue, +168% YoY; $380.9M Cash; ANKTIVA Expands to 5 Jurisdictions, BCG-Naïve Trial Enrolled, NCCN Guideline Update
ImmunityBio, Inc. Common Stock · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · Now $7.24
+9.7% in 1d after detection
Post-detection moves
1h
—
1d
+9.7%
3d
+4.6%
7d
+3.1%
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS